Don’t People Just Sell Their Suboxone?

Why People Worry About Suboxone Diversion

This is a fair question.

Suboxone is a controlled medication. It has street value. Some people do sell it, share it, trade it, or take it in ways other than prescribed. Families, courts, employers, and patients themselves may wonder whether prescribing Suboxone is just creating another medication problem.

That concern should not be brushed aside. Any clinic that prescribes buprenorphine should have a thoughtful plan for safety, monitoring, and accountability.

But the concern also deserves a fuller answer. Suboxone diversion is real, but it is often not as simple as “people are just selling their medication to get high.”

Why Suboxone Has Street Value

Suboxone has street value because opioid withdrawal is miserable, opioid addiction is dangerous, and buprenorphine works.

Many people who use non-prescribed Suboxone are not using it as their preferred drug. They are using it to avoid withdrawal, get through the day without fentanyl or heroin, taper themselves, or bridge a gap when they cannot get into treatment.

That does not make diversion safe or appropriate. Taking Suboxone without medical guidance can still create problems. The dose may be wrong. The timing may be wrong. The person may still be using other substances. There may be medical or psychiatric issues that are not being addressed. And when medication is bought or shared outside of care, there is no treatment plan, no monitoring, and no support if things go badly.

But understanding why people seek Suboxone outside of treatment matters. It tells us that diversion is not only a medication-control problem. It is also an access-to-care problem.

If someone is buying Suboxone on the street to avoid fentanyl, that is not the same clinical situation as someone selling medication for profit while continuing to use opioids. Both situations matter, but they do not mean the same thing.

What Responsible Clinics Do to Reduce Risk

Responsible Suboxone treatment includes structure.

At Shoreline, monitoring is not meant to shame patients. It is part of safe medical care. Depending on the person’s stage of treatment and level of stability, this may include regular follow-up visits, urine drug testing, confirmatory testing when needed, prescription drug monitoring program checks, medication counts, shorter prescriptions early in treatment, and closer follow-up when concerns arise.

Patients who are early in treatment usually need more structure. Patients who are stable over time may be able to move toward longer follow-up intervals. If concerns develop, the level of monitoring may increase again.

This is not unique to addiction treatment. In many areas of medicine, the level of follow-up depends on risk, stability, and how well the treatment plan is working. Blood pressure medications, blood thinners, diabetes medications, psychiatric medications, and pain medications all require different levels of monitoring depending on the situation.

Suboxone treatment is no different in that sense. The medication is effective, but it needs to be prescribed responsibly.

Monitoring Should Not Become a Barrier to Treatment

There is a balance.

If a clinic has no structure, diversion risk goes up. But if a clinic makes treatment too difficult, people may avoid care altogether. They may go back to fentanyl, buy medication on the street, or try to manage withdrawal alone.

That is the tension at the center of this issue.

The answer to diversion cannot be to make Suboxone treatment so restrictive that only the most resourced, organized, and stable patients can access it. Many people with opioid use disorder are trying to rebuild their lives while dealing with transportation problems, work schedules, childcare, shame, financial pressure, legal issues, and years of difficult experiences with the healthcare system.

Good addiction treatment should have standards. It should also be realistic.

The purpose of monitoring is to support safe treatment, not to create a system where patients are expected to prove they are worthy of help.

Trust and Accountability Can Exist Together

Some people think addiction treatment has to choose between trust and accountability. We do not see it that way.

Trust without accountability can become unsafe. Accountability without trust can become punitive and ineffective.

The best treatment lives in the middle. Patients should be treated with dignity. Concerns should be discussed directly. Expectations should be clear. Monitoring should be explained. And when problems happen, the response should be based on clinical judgment, not anger or stigma.

If someone is struggling, the next step may be more frequent visits, a medication count, a change in prescription length, a higher level of care, involvement of supports, or a conversation about what is making the plan hard to follow. In some situations, a clinic may decide that it cannot safely continue prescribing in the same way. But even then, the goal should be safety and connection to appropriate care, not abandonment.

How Shoreline Thinks About This

At Shoreline, we believe Suboxone treatment should be both accessible and responsible.

We know diversion can happen. We also know that buprenorphine saves lives, reduces illicit opioid use, lowers overdose risk, and helps many people return to work, family, health, and stability.

Those truths are not in conflict.

Taking diversion seriously does not mean treating Suboxone as a failed treatment. It means prescribing it carefully. It means paying attention. It means adjusting the treatment plan when risk changes. It means recognizing that medication access, patient trust, and safety all matter.

When people ask, “Don’t people just sell their Suboxone?” the honest answer is:

Sometimes diversion happens, and it should not be ignored. But the bigger picture is more complicated. Many people seek Suboxone outside of treatment because they are trying to avoid withdrawal, reduce opioid use, or survive in a system where getting care can be harder than getting drugs.

That is exactly why responsible treatment matters.